Stay updated on Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page
- Check2 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed content. The detailed study information and related navigation are effectively hidden behind an access-block page.SummaryDifference16%

- Check9 days agoChange DetectedThe website_changes section shows no additions or deletions, indicating the page content remains the same according to the supplied data.SummaryDifference0.0%

- Check16 days agoChange DetectedA new study site was added in Sfax, Tunisia (1053), expanding enrollment options. The prior Tunisia site entry (1053) was removed.SummaryDifference0.4%

- Check23 days agoChange DetectedThe page adds two NIH grant entries (2018 and 2023) and updates the revision to v3.6.6, while the previous revision v3.6.5 is removed.SummaryDifference0.1%

- Check43 days agoChange DetectedThe study record now lists LEO Pharma as sponsor and includes key personnel roles along with a revision tag (Revision: v3.6.5) to reflect the latest data; deletions remove older Boehringer Ingelheim data-sharing policy text and related IPD plan details from the page.SummaryDifference0.8%

- Check58 days agoChange DetectedThe study locations list was updated to include Universitätsklinikum Erlangen in Erlangen, Germany, bringing the total sites to 58, and Zenith Skin Science Center Inc. was added while Center for Skin Research, Testing and Product Development was removed.SummaryDifference0.3%

Stay in the know with updates to Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.